References

1. Quehenberger O, Armando AM, Brown AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010;51:3299-305.

2. Dennis EA, Deems RA, Harkewicz R et al. A mouse macrophage lipidome. J Biol Chem 2010;285:39976-85.

3. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011;17:594-603.

4. Kontush A, Therond P, Zerrad A et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007;27:1843-9.

5. de Souza JA, Vindis C, Hansel B et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008;197:84-94.

6. Stegemann C, Drozdov I, Shalhoub J, et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet 2011;4:232-42.

7. Ray KK, Cannon CP, McCabe CH, et al; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-10.

8. Meikle PJ, Wong G, Tsorotes D, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2011;31:2723-32.

9. Ford DA. Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia. Clin Lipidol 2010;5:835–52.

10. White AJ, Duffy SJ, Walton AS et al. Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease. Cardiovasc Res. 2007;75:813–20.

11. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.

12. Hiukka A, Leinonen E, Jauhiainen M, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007;50: 2067–75.

13. Taskinen M-R, Sullivan DR, Ehnholm C, et al. Relationships of HDL cholesterol, apoA-I, and apoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009;29: 950–5.

14. Yetukuri L, Huopaniemi I, Koivuniemi A et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD Substudy. PLoS One. 2011;6:e23589.

15. Gorgas K, Teigler A, Komljenovic D, Just WW. The ether lipid-deficient mouse: Tracking down plasmalogen functions. Biochimica et Biophysica Acta 2006;1763: 1511–526.